Literature DB >> 27819370

Competitive profiling of celastrol targets in human cervical cancer HeLa cells via quantitative chemical proteomics.

Yiqing Zhou1, Weichao Li2, Mingli Wang3, Xixi Zhang4, Haibing Zhang5, Xiaofeng Tong6, Youli Xiao2.   

Abstract

Celastrol, isolated from the traditional Chinese medicinal herb Tripterygium wilfordii Hook. f. (Thunder God's Vine), has been used to treat cancer, chronic inflammatory, autoimmune and other human diseases. However, to date, the protein targets and the mechanism of action of celastrol have remained elusive. In this study, we find that celastrol can react with protein thiols in a unique covalent and reversible manner, while protein denaturing disrupts the interaction. Through a competitive chemoproteomics approach utilizing a cysteine-targeting activity-based probe, we report the proteome-wide quantitative profiling of cellular targets of celastrol in human cervical cancer HeLa cells. Representative targets are further validated via in vitro binding experiments and/or enzymatic activity assays. Bioinformatics analysis results suggest that celastrol exerts its numerous therapeutic effects through interaction with promiscuous proteins involved in various biological processes and cellular pathways.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27819370     DOI: 10.1039/c6mb00691d

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  13 in total

Review 1.  Reactive-cysteine profiling for drug discovery.

Authors:  Aaron J Maurais; Eranthie Weerapana
Journal:  Curr Opin Chem Biol       Date:  2019-03-18       Impact factor: 8.822

2.  Covalent Ligand Discovery against Druggable Hotspots Targeted by Anti-cancer Natural Products.

Authors:  Elizabeth A Grossman; Carl C Ward; Jessica N Spradlin; Leslie A Bateman; Tucker R Huffman; David K Miyamoto; Jordan I Kleinman; Daniel K Nomura
Journal:  Cell Chem Biol       Date:  2017-09-14       Impact factor: 8.116

3.  ICBS 2017 in Shanghai-Illuminating Life with Chemical Innovation.

Authors:  Qi Zhang; Jingyu Zhang; Evripidis Gavathiotis
Journal:  ACS Chem Biol       Date:  2018-05-02       Impact factor: 5.100

4.  Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.

Authors:  Qilong Tan; Ziqun Liu; Xiaobo Gao; Yibo Wang; Xuefeng Qiu; Jiahui Chen; Liuchun Liang; Hongqian Guo; Shengsong Huang; Denglong Wu; Bing Zhou; Ronggui Hu; Zhenfei Li
Journal:  Oncogene       Date:  2022-09-16       Impact factor: 8.756

5.  Induction of Paraptosis by Cyclometalated Iridium Complex-Peptide Hybrids and CGP37157 via a Mitochondrial Ca2+ Overload Triggered by Membrane Fusion between Mitochondria and the Endoplasmic Reticulum.

Authors:  Kenta Yokoi; Kohei Yamaguchi; Masakazu Umezawa; Koji Tsuchiya; Shin Aoki
Journal:  Biochemistry       Date:  2022-04-01       Impact factor: 3.321

6.  In vitro 3D phenotypic drug screen identifies celastrol as an effective in vivo inhibitor of polycystic kidney disease.

Authors:  Tijmen H Booij; Wouter N Leonhard; Hester Bange; Kuan Yan; Michiel Fokkelman; Anna J Plugge; Kimberley A M Veraar; Johannes G Dauwerse; Gerard J P van Westen; Bob van de Water; Leo S Price; Dorien J M Peters
Journal:  J Mol Cell Biol       Date:  2020-08-01       Impact factor: 6.216

7.  Celastrol alleviates comorbid obesity and depression by directly binding amygdala HnRNPA1 in a mouse model.

Authors:  Chunyan Zhu; Jun Yang; Yongping Zhu; Jiahao Li; Hongyu Chi; Congmin Tian; Yuqing Meng; Yanqing Liu; Jigang Wang; Na Lin
Journal:  Clin Transl Med       Date:  2021-06

Review 8.  Nanotechnology-Based Celastrol Formulations and Their Therapeutic Applications.

Authors:  Pushkaraj Rajendra Wagh; Preshita Desai; Sunil Prabhu; Jeffrey Wang
Journal:  Front Pharmacol       Date:  2021-06-11       Impact factor: 5.810

9.  Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation.

Authors:  Xianjun Yu; Qun Zhao; Xixi Zhang; Haiwei Zhang; Yongbo Liu; Xiaoxia Wu; Ming Li; Xiaoming Li; Jingxuan Zhang; Xuzhi Ruan; Haibing Zhang
Journal:  Oncotarget       Date:  2017-06-27

10.  Preparation of high drug-loading celastrol nanosuspensions and their anti-breast cancer activities in vitro and in vivo.

Authors:  Tiantian Huang; Yian Wang; Yiping Shen; Hui Ao; Yifei Guo; Meihua Han; Xiangtao Wang
Journal:  Sci Rep       Date:  2020-06-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.